Trial Profile
A Randomised, Double-blind, Single Centre, Two-way Cross-over Trial Comparing the Pharmacokinetics, Pharmacodynamics and Safety of the Biphasic Insulin Aspart 30 and Insulin Mixtard 30/70 After Multiple Dosing With a Twice Daily Dose Regimen in Type 2 Diabetic Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Insulin aspart/insulin protamine aspart (Primary) ; Neutral insulin injection/insulin suspension isophane
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 27 Apr 2015 New trial record